|Mr. Steven Adam Lisi||CEO & Chairman||450k||N/A||1971|
|Mr. Amir Avniel||Co-Founder, Pres & Chief Bus. Officer||400k||N/A||1974|
|Mr. Douglas Quinton Larson||CFO, Principal Financial Officer & Principal Accounting Officer||274.95k||N/A||1971|
|Mr. Michael A. Gaul||Chief Operating Officer||N/A||N/A||1955|
|Ms. Maria Yonkoski||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Adam Newman||Chief Legal Officer & Gen. Counsel||N/A||N/A||N/A|
|Ms. Rebecca Van Doren||Head of Sales||N/A||N/A||N/A|
|Ms. Kori-Ann Taylor||Head of Marketing||N/A||N/A||N/A|
|Prof. Andrew R. Colin M.D.||Chief Medical Officer & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Giora Davidai M.D.||Chief Medical Officer||N/A||N/A||N/A|
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Beyond Air, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.